BCL2A1 and cancer: A model has been proposed that SF3B-targeting splicing modulators preferentially perturb RNA splicing of MCL1 and BCL2A1, but not of BCL2L1 (BCLxL), leading to selective cytotoxicity in MCL1- or BCL2A1-dependent cancer cells.